|Bid||6.69 x 1100|
|Ask||6.70 x 800|
|Day's Range||6.58 - 7.03|
|52 Week Range||3.50 - 18.24|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.75|
AVEO (AVEO) delivered earnings and revenue surprises of -30.91% and 42.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
NEW YORK, NY / ACCESSWIRE / May 10, 2021 / AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time.